Semaglutide for the management of diabesity: The real-world experience

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

374

Figures (1-3)

Tables (1-6)

Sum=505

Publishing Process of This Article

Item

Count

Browse

Download

Sum=33

Sep 20, 2024 (publication date) through Jul 17, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Methodol. Sep 20, 2024; 14(3): 91832
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91832

Table 6 Daily insulin requirement before and after treatment with semaglutide

Attributes	Male		Female		All
Attributes	Mean	(SD)	Mean	(SD)	Mean	(SD)
Daily insulin dose baseline (units)	106.00	(83.59)	81.89	(58.48)	95.02	(74.02)
Daily insulin dose latest (units)	92.2	(62.86)	62.14	(46.21)	76.45	(56.17)

Citation: Alkhalifah M, Afsar H, Shams A, Blaibel D, Chandrabalan V, Pappachan JM. Semaglutide for the management of diabesity: The real-world experience. World J Methodol 2024; 14(3): 91832
URL: https://www.wjgnet.com/2222-0682/full/v14/i3/91832.htm
DOI: https://dx.doi.org/10.5662/wjm.v14.i3.91832